The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Nothing like Hippo for cooling investor enthusiasm
Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.